Navigation Links
Optimer Pharmaceuticals' Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer
Date:2/27/2013

ents, including, without limitation, statements related to the expected impact of Optimer's recent personnel changes, Optimer's review of strategic alternatives including a possible sale of the Company, Optimer's expected financial results for the fourth quarter and year ended December 31, 2012, the implementation and impact of Optimer's commercialization strategy, expansion of DIFICID sales or market potential and the expected impact of Optimer's independent investigation and previously disclosed cooperation with relevant U.S. authorities.  Words such as "expect," "anticipate," "will," "could," "would," "project," "intend," "plan," "believe," "predict," "estimate," "should," "may," "potential," "continue," "ongoing" or variations of such words and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. These forward-looking statements are based on management's expectations on the date of this release. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: Optimer's ability to continue driving adoption and use of DIFICID, the implementation and success of DIFICID growth initiatives and entry into new markets, whether healthcare professionals will prescribe DIFICID, the extent to which DIFICID receives reimbursement coverage from healthcare payors and government agencies, the extent to which DIFICID will be accepted on additional hospital formularies and the timing of hospital formulary decisions, Optimer's ability to successfully coordinate commercialization efforts with Cubist Pharmaceuticals under its co-promotion agreement, whether Optimer will be able to realize expected benefits under its co-promotion agreement with Cubist and its collaboration agreements with other partn
'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
2. Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference
3. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
4. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences
5. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results
6. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences
7. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
9. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results
10. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
11. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. (OTC ... U.S. provisional patent application concerning composition of matter, biological ... targeted tumor cell death.  This patent ... double stranded RNA molecules (VSRNAs) which interfere with the ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/17/2014)... of the most popular vaccine brands for children may ... be overlooking some cost factors when choosing vaccines, driving ... option, according to a new study by University of ... can be driven by numerous factors," says Sheldon H. ... of computer science and of mathematics at the U. ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... April 17, 2014U.S. military personnel who served in ... concussive traumatic brain injury (TBI) were compared to ... other medical reasons. Differences in measures of overall ... months after injury are reported in an article ... journal from Mary Ann Liebert, Inc., publishers. The ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... (SACRAMENTO, Calif.) An international team led by researchers ... protein complex, which plays a key role in cell ... process. This is the first time the complex has ... could make cyclin B1/Cdk1 an excellent target to control ... medicine. The research was published online today in the ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... recurrence of an employee,s medical leave of absence from work tends ... physical one, a Centre for Addiction and Mental Health (CAMH) study ... from their jobs do not have another disability leave for at ... contrast, most who have had a physical health disability leave have ...
... Reporter , TUESDAY, June 28 (HealthDay News) -- A vaccine ... some promise, while another designed to alter insulin production fails, ... results of both studies were slated to be presented Tuesday ... Type 1 diabetes often appears early in life and ...
... with life,s punches, while for others, every misfortune is a jab ... although most people require significant adversity to become depressed the ... 30 percent of people with first-time depression and 60 percent of ... minor misfortunes. But no one knew why. Now, ...
... , TUESDAY, June 28 (HealthDay News) -- ... to the flu vaccine, which suggests that the drugs ... as previously believed, researchers say. The small study ... were treated with sunitinib and six who were treated ...
... Diego, Calif., has joined a national consortium of research institutions ... library of primary human tumors with the goal of developing ... consortium member, STSI will provide solid human tumor samples to ... study. STSI scientists will then have access to the models ...
... Science University have discovered a naturally occurring disease in monkeys ... a discovery that could have a major impact on efforts ... disease that the researchers discovered in monkeys at OHSU,s Oregon ... that could give significant clues into how multiple sclerosis develops ...
Cached Medicine News:Health News:Workplace mental health disability leave recurs sooner than physical health leave, CAMH study shows 2Health News:Trials of Type 1 Diabetes Vaccines Bring Mixed Results 2Health News:Trials of Type 1 Diabetes Vaccines Bring Mixed Results 3Health News:Sweating the small stuff: Early adversity, prior depression linked to high sensitivity to stress 2Health News:Sweating the small stuff: Early adversity, prior depression linked to high sensitivity to stress 3Health News:Certain Cancer Drugs Don't Interfere With Flu Vaccine: Study 2Health News:Scripps Translational Science Institute joins Jackson Laboratory tumor consortium 2Health News:Researchers at Oregon Health & Science University discover MS-like disease in monkeys 2
All Keeler magnifiers and telescope are available on a clip to fit over the patient's own spectacle...
This set offers the full range of Keeler magnifiers and telescopes....
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
Significantly more compact and tidier in overall looks yet retain many of the excellent features of the more comprehensive Haag type systems., ,Filters include Cobalt blue; green (red free); neut...
Medicine Products: